Trader consensus on a low likelihood of a new COVID variant of concern before 2027 stems primarily from sustained global genomic surveillance showing no lineages meeting WHO or ECDC VOC criteria as of mid-2026. Omicron descendants such as XFG, NB.1.8.1, and BA.3.2 circulate as variants under monitoring, with BA.3.2 displaying notable spike mutations yet low U.S. prevalence around 0.2 percent and no evidence of heightened severity or widespread immune escape driving hospitalizations. European detections of BA.3.2 rose in late 2025 but remained regionally contained without triggering reclassification. Public health agencies continue assessing overall risk as low given population immunity from prior infections and vaccines, supporting the view that incremental evolution rather than a qualifying new variant is the near-term baseline.